What's in Store for West Pharmaceutical in Q3 Earnings?
WST's third-quarter 2024 results are likely to reflect weakness in its Proprietary Products business. Unfavorable currency movements might have hurt the top and bottom lines.
| Ticker |
Sentiment |
Impact |
|
CURN
|
Neutral
|
6 %
|
|
MASI
|
Neutral
|
11 %
|
|
WST
|
Neutral
|
43 %
|
|
ACAD
|
Neutral
|
11 %
|
|
BDX
|
Neutral
|
11 %
|
